A Study of Golimumab in Participants With Active Psoriatic Arthritis A golimumab vizsgálata aktív ízületi gyulladásban szenvedő betegeknél The primary objective of this study is to evaluate the efficacy of IV administration of golimumab 2 mg/kg in subjects with active psoriatic arthritis (PsA) by assessing the reduction in signs and symp...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Extended-Release Paliperidone as Maintenance Treatment After an Acute Manic or Mixed Episode Associated With Bipolar I Disorder The primary objectives of this study are to evaluate the efficacy of extended-release paliperidone (paliperidone ER) compared with placebo in the prevention of the recurrence of any mood symptoms (i.e...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Early Access Treatment with Daratumumab for (Relapsed or Refractory) Multiple Myeloma Acceso al Tratamiento precoz con Daratumumab para (recidivante o resistente) Mieloma Múltiple The objective of this study is to provide early access to daratumumab treatment and collect additional safety data while the medication is not commercially available for subjects with multiple myeloma...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

CR100840 : Essai de phase 3 randomisé, en double aveugle, évaluant l’efficacité et la tolérance d’une thérapie ciblée, l’ibrutinib, , inhibiteur de la tyrosine kinase de Bruton, en association avec la bendamustine et le rituximab, chez des patients ayant une leucémie lymphoïde chronique ou un lymphome lymphocytique réfractaire ou en rechute. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] L’objectif de cet essai est d’évaluer l’efficacité et la tolérance de l’ibrutinib en association avec de la bendamustine et du rituximab, chez des patients ayant une leucémie lymphoïde chronique ou un...

• Pays France
• Organes Leucémies chroniques, Lymphomes non hodgkinien
• Spécialités Chimiothérapie, Thérapies Ciblées

A study of Daratumumab combined with Atezolizumab versus Atezolizumab in Previously Treated Subjects with Advanced Non-Small Cell Lung Cancer. Estudio de daratumumab combinado con atezolizumab frente a atezolizumab en sujetos con cáncer de pulmón no microcítico avanzado o metastásico tratados previamente To compare the overall response rate (ORR) in subjects treated with daratumumab in combination with atezolizumab versus atezolizumab alone. Comparar la tasa de respuesta global (ORR, overall res...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002 Estudio de la seguridad, eficacia de Fulranumab en monoterapia en sujetos con artrosis de cadera o rodilla, PAI3002 The primary objective is to demonstrate the efficacy using 2 co-primary endpoints (as measured by the changes from baseline to the end of Week 16 in Western Ontario and McMaster University Osteoarthri...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Étude CR108064 : étude de phase 1 évaluant une escalade de dose du JNJ-61186372, chez des patients ayant une cancer du poumon non à petites cellules avancé. A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer

• Pays France
• Organes Poumon, type non à petites cellules
• Spécialités Immunothérapie - Vaccinothérapie

A Study to Evaluate the Safety, Tolerability, and Efficacy of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK2336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Chronic Genotype-1 Hepatitis C Infected Patients - Evaluate safety and tolerability of 12 weeks dosing regimen containing TMC647055 once daily (q.d.), TMC435 q.d., and RTV q.d., at selected doses with and without RBV (2 daily doses) in chronic HCV g...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Daratumumab Open label, dose-escalation safety study in Combination with Lenalidomide and Dexamethasone in Patients with multiple myeloma To establish the safety profile of daratumumab when given in combination with Len/Dex in subjects with relapsed or relapsed and refractory multiple myeloma

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Detection of Aspergillus Fumigatus and Sensitization in COPD Patients With Bronchiectasis vs Without Bronchiectasis A single center case-control study with 100 COPD patients will be organized to compare patients with and without bronchiectasis with regard to the presence of Aspergillus in sputum samples...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune